Medical Balloon Manufacturing Market Global Report 2026

The medical balloon manufacturing market size has grown strongly in recent years. It will grow from $0.91 billion in 2025 to $0.97 billion in 2026 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to increasing adoption of minimally invasive procedures, rising demand for catheter-based medical devices, growing use of angioplasty and dilatation balloons, increasing need for precision medical device components, and growing demand for reliable balloon performance.

The medical balloon manufacturing market size is expected to see strong growth in the next few years. It will grow to $1.21 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. Growth during the forecast period is anticipated to result from rising demand for next-generation specialty medical balloons, increasing use of advanced polymer materials, growing need for ultra-thin balloon walls, wider adoption of automated balloon manufacturing processes, and increasing demand for high-pressure and high-compliance balloon designs. Major trends during the forecast period include greater adoption of ultra-thin medical balloon designs, rising demand for high-pressure balloon manufacturing, increased use of advanced polymer forming technologies, growing need for precise balloon dimensional control, and wider adoption of highly flexible and conformable balloon structures.

The increasing prevalence of cardiovascular diseases is expected to propel the growth of the medical balloon manufacturing market going forward. Cardiovascular diseases (CVDs) refer to a group of disorders affecting the heart and blood vessels, including coronary artery disease, heart attack, stroke, heart failure, arrhythmias, and peripheral artery disease. The prevalence of cardiovascular diseases is increasing due to rising rates of hypertension, obesity, physical inactivity, and unhealthy dietary patterns, which contribute to arterial damage and atherosclerosis. Medical balloon manufacturing supports cardiovascular disease management by enabling minimally invasive procedures such as angioplasty and stent placement. These balloons help restore blood flow by expanding narrowed or blocked blood vessels, reducing the need for open surgery and supporting faster patient recovery. For instance, in February 2026, according to the American Heart Association, a US-based nonprofit organization focused on cardiovascular health, six in 10 U.S. adults are projected to have cardiovascular disease by 2050, driven by population aging and increasing cardiovascular risk factors. Additional projections indicate that heart valve disease could double by 2040 and triple by 2060, further increasing the need for cardiovascular interventions and catheter-based treatment technologies. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the medical balloon manufacturing market.

Major companies operating in the medical balloon manufacturing market are concentrating on developing advanced products, such as next-generation intravascular lithotripsy (IVL) catheters, to address unmet clinical requirements related to deliverability, lesion crossing, and balloon repositioning in the treatment of calcified coronary artery disease. Next-generation IVL catheters refer to advanced balloon-based systems that use ultrasonic acoustic pressure waves to fracture hardened calcium while incorporating enhanced shaft flexibility, tapered tips with hydrophilic coatings, and improved balloon deflation for easier navigation and repositioning within tortuous arteries. For instance, in May 2026, Johnson & Johnson, a US-based medical technology company, launched the Shockwave C2 Aero Coronary IVL Catheter, a next-generation balloon-based intravascular lithotripsy catheter designed to enhance deliverability through tortuous coronary anatomy, facilitate the crossing of heavily calcified lesions, and support balloon repositioning. The device incorporates a more flexible balloon material, a tapered tip, a hydrophilic coating, and compact balloon deflation and rewrapping capabilities. These advancements require precise balloon forming, specialized material processing, catheter assembly, and stringent quality-control technologies, thereby supporting innovation in medical balloon manufacturing.

In September 2024, Quasar Medical, a US-based manufacturer of complex minimally invasive medical devices, acquired Ridgeback Technologies Ltd. for an undisclosed amount. The acquisition expanded Quasar Medical's internal capabilities in balloon design, prototyping, mold manufacturing, extrusion, injection molding, and catheter assembly, strengthening its end-to-end medical balloon manufacturing capabilities and supporting faster scale-up and customized balloon catheter production. Ridgeback Technologies Ltd. is a US-based medical device company specializing in the design, development, and manufacture of catheter balloons and complete balloon catheter assemblies.

Major companies operating in the medical balloon manufacturing market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Becton Dickinson and Company, Terumo Corporation, Integer Holdings Corporation, B. Braun SE, Cook Group Incorporated, Cordis Corporation, BIOTRONIK SE & Co. KG, Kaneka Corporation, Merit Medical Systems Inc, Lepu Medical Technology (Beijing) Co. Ltd, OrbusNeich Medical Company Ltd, Biomerics LLC, Endologix LLC, BrosMed Medical Co. Ltd, Tokai Medical Products Inc, Hexacath SA, NATEC Medical Ltd, iVascular S.L.U., Balton Sp. z o.o., Concept Medical Inc.

North America was the dominating region in the medical balloon manufacturing market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the medical balloon manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the medical balloon manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The medical balloon manufacturing consists of sales of cutting balloons, scoring balloons, lithotripsy balloons, perfusion balloons and embolectomy balloons. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream medical device manufacturers, catheter assemblers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

This product will be delivered within 3-5 business days.